BEYOND study is designed to generate the first real-world data from GCC countries on the patient characteristics, treatment patterns, survival outcomes, and safety of T-DXd in patients with HRpositive,HER2-low or HER2-ultralow mBC previously treated with ET. The evidence generated will help to optimise treatment strategies, inform clinical guidelines, and ultimately improve outcomes for patients with mBC across the region.
-Female patients aged ≥18 years old at the time of T-DXd initiation
Patients with a confirmed histological or cytologically based diagnosis of HR-positive mBC.
HER2-low status defined as IHC scores 1+ and 2+ without ISH gene amplification based on the pathology report.
HER2-ultralow status defined as IHC 0 with membrane staining based on the pathology report.
-Patients with a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.
Patients who received prior chemotherapy in the metastatic setting.
Patients with Eastern Cooperative Oncology Group (ECOG) status ≥2 or missing ECOG status at the time of initiation of T-DXd (index date).
Patients with a history of participation in another clinical trial in the metastatic setting.